Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 4/20 | 0.58 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.58 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.58 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.58 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.58 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.58 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | DAO | P14920 | 2/20 | 0.55 |
| ▸ | DDO | Q99489 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 2/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31236118 | 1.00 | GRIN2D (0.58) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8873322 | 0.91 | DAO (0.52) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL172143 | 0.86 | MAPT (0.54) | KDM4EMAPTCA12CA9NOS1 | |
| SCHEMBL30211032 | 0.85 | GRIN2D (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8873683 | 0.80 | KIF11 (0.52) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3277444 | 0.76 | ALDH1A1 (0.58) | KDM4EHSD17B10MAPTALDH1A1 | |
| SCHEMBL19451945 | 0.76 | KIF11 (0.42) | KDM4EDAOHSD17B10MAPTCA12 | |
| SCHEMBL16381141 | 0.74 | DAO (0.68) | KDM4EDAODDOHSD17B10MAPT | |
| SCHEMBL15478601 | 0.74 | DAO (0.68) | KDM4EDAODDOHSD17B10MAPT | |
| SCHEMBL20792931 | 0.74 | PARP1 (0.56) | KDM4EDAODDOHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4367103-A1 | INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2024-05-15 | — | — | EP | disclosed |
| EP-3573960-B1 | N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXAZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES | GENFIT (FR) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023280970-A1 | INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2023-01-12 | — | — | WO | disclosed |
| EP-2696873-B1 | PLASMODIAL SURFACE ANION CHANNEL INHIBITORS FOR THE TREATMENT OR PREVENTION OF MALARIA | US HEALTH (US) | 2022-08-03 | — | — | EP | disclosed |
| WO-2018138362-A1 | N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXA ZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES | GENFIT (FR) | 2018-08-02 | — | — | WO | disclosed |
| EP-3318557-A2 | QUINOLONE COMPOUND | Otsuka Pharmaceutical Co., Ltd. (JP) | 2018-05-09 | — | — | EP | disclosed |
| EP-2751083-B1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2017-12-27 | — | — | EP | disclosed |
| US-20160361295-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2016-12-15 | — | — | US | disclosed |
| US-20160015685-A1 | FURO [3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2016-01-21 | — | — | US | disclosed |
| US-9206173-B2 | Heterocyclic compounds for the treatment of stress-related conditions | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | disclosed |
| US-7102000-B2 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | INCYTE SAN DIEGO INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20060160796-A1 | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | PFAHL MAGNUS | 2006-07-20 | — | — | US | disclosed |
| US-7071218-B2 | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | INCYTE SAN DIEGO INCORPORATED (US) | 2006-07-04 | — | — | US | disclosed |
| US-20030216432-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | ORTHO MCNEIL PHARMACEUTICAL INC. | 2003-11-20 | — | — | US | disclosed |
| US-20030144329-A1 | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | ORTHO MCNEIL PHARMACEUTICAL INC. (US) | 2003-07-31 | — | — | US | disclosed |
| US-20030083357-A1 | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia | ORTHO MCNEIL PHARMACEUTICAL INC. | 2003-05-01 | — | — | US | disclosed |
| US-6251903-B1 | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonist | COCENSYS, INC. | 2001-06-26 | — | — | US | disclosed |
| US-6147075-A | ANALGESICS; PSYCHOLOGICAL DISORDERS | COCENSYS, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| US-5977107-A | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonists | COCENSYS, INC. (US) | 1999-11-02 | — | — | US | disclosed |
| US-5631373-A | NERVOUS SYSTEM DISORDERS | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144329-A1 | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | CYP27A1, CYP46A1, PNLIP | GRIN2D 4212/4885GRIN3B 4542/4885GRIN1 4032/4885 |
| US-20060160796-A1 | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | CYP27A1, PC, PNLIP | GRIN2D 4206/4885GRIN3B 4509/4885GRIN1 4257/4885 |
| US-20030083357-A1 | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia | OAT, CPT1A, CYP27A1 | GRIN2D 4715/4885GRIN3B 4610/4885GRIN1 4081/4885 |
| US-20160015685-A1 | FURO [3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | GRIN2D 4552/4885GRIN3B 2994/4885GRIN1 2346/4885 |
| US-20160361295-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | GRIN2D 4515/4885GRIN3B 2457/4885GRIN1 2267/4885 |
| US-20030216432-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | GCKR, HDAC5, GPR119 | GRIN2D 2177/4885GRIN3B 4211/4885GRIN1 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.